Fundraising Fox
neuroLytixs
Techstars '20Toronto, CA · Founded 2020 · 1 employees on LinkedIn · 1 known investors
Find your way into neuroLytixs
Canadian diagnostics company developing an AI-assisted finger-prick blood test for concussion and mild traumatic brain injury.
Also known as Neurolytixs · Neurolytixs Inc.
Investors · 1
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026Neurolytixs Inc. is a Canadian diagnostics company developing a blood-based test for the diagnosis of concussion and mild traumatic brain injury (mTBI). The test uses a finger-prick dried plasma spot sample and measures metabolite markers — described as four lipids whose levels fall in the blood following a concussion — via mass spectrometry, with machine learning and artificial intelligence applied to biomarker interpretation. The company reports accuracy of up to 96% in preliminary peer-reviewed studies, against a stated clinical benchmark that a 70%-accurate test is considered good.
The diagnostic follows a two-step protocol. An individual first records a baseline "chemical fingerprint" by submitting a finger-prick blood sample at the start of a sporting season. If a possible concussion occurs, a second finger-prick sample is sent to the lab within a 72-hour window after the incident and compared against both the individual's baseline and a population reference range, producing a result within 20 minutes. The company positions the test as an objective alternative to concussion diagnosis based on physical, cognitive and behavioural assessment, which it describes as subject to misinterpretation and manipulation, and as a tool to remove injured athletes from play and guide recovery protocols. Management has also cited potential applicability to brain injuries from falls, car crashes and blasts.
The technology originated with a discovery in London, Ontario, and the company has licensed and fully executed the underlying patented technology. Neurolytixs states partnerships with HeadCheck Health, Lawson Health Research Institute/Western University, MaRS, Techstars Accelerators, the Ontario Centre for Innovation and the Ontario Brain Institute.
Founding story
Dr. Douglas Fraser, Peter George and Adrian Uthay founded Neurolytixs after the discovery of a novel blood test for concussion diagnosis in London, Ontario. Fraser, a clinical scientist, is credited as co-founder and developer of the technology, which the company described in 2021 as six years in the making; Peter George serves as CEO, and Dr. Alicia DiBattista as Chief Technology Officer.
Business model
Neurolytixs commercializes a licensed, patented laboratory diagnostic for mild traumatic brain injury. Samples are collected via finger prick as dried plasma spots and analyzed by mass spectrometry in a lab, with a baseline test taken at the start of a sporting season and a follow-up test after a suspected concussion. The company describes a route to market that would put the test in the hands of parents, coaches, teachers, doctors and medical professionals, pending regulatory approval in the US and Europe.
Traction
By September 2021 the company reported peer-reviewed preliminary results with accuracy up to 96%, executed patents in Canada and abroad, and substantial commercial interest across North America. It began clinical trials in Michigan in February 2022 and announced fully executed US patenting in August 2022. Headcount was reported at three employees as of February 2024.
Latest developments
In August 2022 Neurolytixs announced it had obtained fully executed US patenting for its concussion diagnostic technology and that clinical trials, begun in Michigan in February 2022 following an FDA pre-submission review, were under way on the path toward full FDA approval.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Neurolytixs operates in concussion and traumatic brain injury diagnostics, an area it describes as a multibillion-dollar global industry in which it aims to be a first mover with a blood-based test. Companies identified as similar include Brainbox Solutions, Cerebro NeuroTech, Synaptek and ZelosDx.
The company argues that while other concussion-assessment devices exist, blood is the definitive means of determining whether a concussion has occurred, and positions its metabolite-marker panel with a reported accuracy of up to 96% against a clinical norm in which 70% accuracy is considered acceptable. It has stated an intention to be first-mover in the global concussion diagnostics market on the basis of its licensed and executed patents in Canada, the United States and internationally.
Technology
The diagnostic measures metabolite biomarkers — four lipids that decline in blood after a concussion — from dried plasma spots collected by finger prick and quantified by mass spectrometry. Machine learning and artificial intelligence support biomarker discovery and interpretation, comparing a post-incident sample taken within 72 hours against the individual's pre-season baseline and a population reference range.
Go-to-market
Early activity has centred on amateur and youth sports, with baseline testing at the start of a sporting season and post-incident testing administered by parents, coaches, teachers and medical professionals. The company has pursued regulatory validation through FDA pre-submission and clinical trials, and works with research and accelerator partners including Lawson Health Research Institute/Western University, MaRS, Techstars, the Ontario Centre for Innovation and the Ontario Brain Institute, together with concussion-management company HeadCheck Health.
Primarily amateur and youth sports, where the company cites that more than 10% of young athletes experience a concussion each year and about 50% of concussions go undiagnosed. The test is intended for administration by parents, coaches, teachers, doctors and medical professionals in households, schools and clinics, with potential extension to patients injured in falls, car crashes and blasts.
Geography
The technology originated in London, Ontario, and the company's headquarters is listed in Toronto, Ontario, Canada. Clinical trials began in the State of Michigan in February 2022, and the company has cited plans to pursue regulatory approval in the United States and Europe and commercial interest across North America.
History
The company was founded in 2020 in London, Ontario, following the discovery of a novel blood test for concussion diagnosis, and was selected that year as one of ten companies in the Techstars Montréal AI Accelerator cohort. In September 2021 it publicly announced its diagnostic technology and stated that patents had been executed in Canada and internationally, that large-scale clinical trials were being designed, and that a first pivotal study was on track to begin by Q1 2022. Clinical trials commenced in the State of Michigan in February 2022 after an FDA pre-submission review. In August 2022 the company announced fully executed US patenting for the technology.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsCompany stated it works in partnership with HeadCheck Health, Lawson Health Research Institute/Western University, MaRS/Techstars Accelerators, Ontario Centre for Innovation and the Ontario Brain Institute.
Neurolytixs Inc. announced it had secured fully executed US patenting for its blood-metabolite-based concussion diagnostic technology.
Neurolytixs began clinical trials in the State of Michigan after obtaining a pre-submission review from the U.S. FDA, placing the technology on a regulatory path toward FDA approval.
Company announced a two-step diagnostic process using a baseline dried plasma spot sample and a post-incident finger-prick sample analyzed by mass spectrometry, with results in 20 minutes and reported accuracy of up to 96% in peer-reviewed preliminary studies.
Neurolytixs was one of ten companies chosen for the Techstars Montréal AI Accelerator 2020 cohort; Techstars is described as an early investor in the company.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Neurolytixs' breakthrough technology revolutionizing concussion diagnosisprnewswire.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does neuroLytixs do?
- Canadian diagnostics company developing an AI-assisted finger-prick blood test for concussion and mild traumatic brain injury.
- Who are neuroLytixs's investors?
- neuroLytixs's investors include Techstars.
- Where is neuroLytixs headquartered?
- neuroLytixs is headquartered in Toronto, CA.